MGM-15 Limited data

Limited data

Sparse data. Doses and effects may be unreliable or untested.

• 1 source
• no dose data
• 19 combo interactions documented
• classified Research-chemical
• dose data not in PW/TripSit (unverifiable)

Summary dose.wiki

MGM-15 (dihydro-7-hydroxymitragynine, CAS 1158901-38-2) is a semi-synthetic opioid made by reducing the C=N bond of 7-hydroxymitragynine, the active metabolite of the kratom alkaloid mitragynine. It is not a natural kratom constituent and not a known human metabolite. It was developed by Matsumoto et al. (2014) alongside MGM-16, its 9-fluoro analogue, as μ/δ dual opioid agonists. In animal models the DEA describes MGM-15 as roughly 50 times more potent than morphine. That figure is rodent data and does not translate to a human dose. It has never been studied in humans: no published human dose, no pharmacokinetics, no controlled administration. It reached the US market as tablets sold as a “research chemical”, and every sample confirmed so far has been a mixture also containing mitragynine and 7-hydroxymitragynine. The DEA placed it into Schedule I in July 2026. MGM-15 is not mitragynine pseudoindoxyl (CAS 2035457-43-1) and not MGM-16. The DEA scheduled all three as separate substances. They have different structures and different potencies, and dosing or pharmacology information for one does not transfer to another.

Dose Information dose.wiki

Dose basis. There is no reliable public data on human doses of MGM-15. We cannot tell you a safe amount, and anyone publishing a milligram range for this compound is guessing — so this page does not carry a dose ladder. What is actually documented: retail products have carried label claims of 3.5 mg, 15 mg and 30 mg per unit (DEA, 2026), and one analytical study measured tablets at an average 10.9 mg each (Gour et al., Drug Testing and Analysis, 2025). Those are vendor amounts in unverified mixtures, spanning nearly a tenfold range — evidence of how inconsistent the market is, not guidance. Because every confirmed sample also contained mitragynine and 7-hydroxymitragynine, user-reported milligrams are milligrams of an unknown blend. A previous version of this page carried a 15–40 mg “common” oral range with no source behind it. It was removed on 2 August 2026 after a reader reported a near-overdose at 20 mg. Treat MGM-15 as a full μ-opioid agonist: assume respiratory depression, keep naloxone to hand, never dose alone, and never combine with other depressants.

Effects dose.wiki

Combinations

Helpful Links